Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: Biologic rationale for combination strategies

David R Gandara, Angela M. Davies, Oliver Gautschi, Philip Mack, Derick H Lau, Primo N Lara, Fred R. Hirsch

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Chemotherapy continues to play an essential role in the treatment of most stages of non-small-cell lung cancer (NSCLC). In fact, within the past 5 years, this role has greatly expanded into adjuvant therapy for early-stage resected disease. Likewise, agents targeting the epidermal growth factor receptor (EGFR), particularly the tyrosine kinase inhibitors gefitinib and erlotinib, have proven to be clinically active in patients with advanced-stage NSCLC. Because of these findings, it is logical to expect that combinations of these 2 classes of antineoplastic agents would prove more efficacious than either one alone. Yet 4 large randomized phase III trials of chemotherapy with or without an EGFR tyrosine kinase inhibitor in unselected patients with advanced-stage NSCLC, altogether totaling > 4000 patients, did not demonstrate improvement in clinical outcomes with the combination. Whether these negative results will be reproduced in ongoing combination studies of chemotherapy plus monoclonal antibodies directed against EGFR remain to be determined. Herein, we review recent preclinical and clinical data addressing this topic and explore the biologic rationale for developing new combination strategies based on patient selection by molecular and clinical factors, or by pharmacodynamic parameters.

Original languageEnglish (US)
JournalClinical Lung Cancer
Volume8
Issue numberSUPPL. 2
DOIs
StatePublished - Feb 2007

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Drug Therapy
Protein-Tyrosine Kinases
Combination Drug Therapy
Antineoplastic Agents
Patient Selection
Monoclonal Antibodies
Therapeutics

Keywords

  • Antineoplastic agents
  • Monoclonal antibodies
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

@article{91e8802f3a914697b24912b43fbcb9e0,
title = "Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: Biologic rationale for combination strategies",
abstract = "Chemotherapy continues to play an essential role in the treatment of most stages of non-small-cell lung cancer (NSCLC). In fact, within the past 5 years, this role has greatly expanded into adjuvant therapy for early-stage resected disease. Likewise, agents targeting the epidermal growth factor receptor (EGFR), particularly the tyrosine kinase inhibitors gefitinib and erlotinib, have proven to be clinically active in patients with advanced-stage NSCLC. Because of these findings, it is logical to expect that combinations of these 2 classes of antineoplastic agents would prove more efficacious than either one alone. Yet 4 large randomized phase III trials of chemotherapy with or without an EGFR tyrosine kinase inhibitor in unselected patients with advanced-stage NSCLC, altogether totaling > 4000 patients, did not demonstrate improvement in clinical outcomes with the combination. Whether these negative results will be reproduced in ongoing combination studies of chemotherapy plus monoclonal antibodies directed against EGFR remain to be determined. Herein, we review recent preclinical and clinical data addressing this topic and explore the biologic rationale for developing new combination strategies based on patient selection by molecular and clinical factors, or by pharmacodynamic parameters.",
keywords = "Antineoplastic agents, Monoclonal antibodies, Tyrosine kinase inhibitors",
author = "Gandara, {David R} and Davies, {Angela M.} and Oliver Gautschi and Philip Mack and Lau, {Derick H} and Lara, {Primo N} and Hirsch, {Fred R.}",
year = "2007",
month = "2",
doi = "10.3816/CLC.2007.s.003",
language = "English (US)",
volume = "8",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer

T2 - Biologic rationale for combination strategies

AU - Gandara, David R

AU - Davies, Angela M.

AU - Gautschi, Oliver

AU - Mack, Philip

AU - Lau, Derick H

AU - Lara, Primo N

AU - Hirsch, Fred R.

PY - 2007/2

Y1 - 2007/2

N2 - Chemotherapy continues to play an essential role in the treatment of most stages of non-small-cell lung cancer (NSCLC). In fact, within the past 5 years, this role has greatly expanded into adjuvant therapy for early-stage resected disease. Likewise, agents targeting the epidermal growth factor receptor (EGFR), particularly the tyrosine kinase inhibitors gefitinib and erlotinib, have proven to be clinically active in patients with advanced-stage NSCLC. Because of these findings, it is logical to expect that combinations of these 2 classes of antineoplastic agents would prove more efficacious than either one alone. Yet 4 large randomized phase III trials of chemotherapy with or without an EGFR tyrosine kinase inhibitor in unselected patients with advanced-stage NSCLC, altogether totaling > 4000 patients, did not demonstrate improvement in clinical outcomes with the combination. Whether these negative results will be reproduced in ongoing combination studies of chemotherapy plus monoclonal antibodies directed against EGFR remain to be determined. Herein, we review recent preclinical and clinical data addressing this topic and explore the biologic rationale for developing new combination strategies based on patient selection by molecular and clinical factors, or by pharmacodynamic parameters.

AB - Chemotherapy continues to play an essential role in the treatment of most stages of non-small-cell lung cancer (NSCLC). In fact, within the past 5 years, this role has greatly expanded into adjuvant therapy for early-stage resected disease. Likewise, agents targeting the epidermal growth factor receptor (EGFR), particularly the tyrosine kinase inhibitors gefitinib and erlotinib, have proven to be clinically active in patients with advanced-stage NSCLC. Because of these findings, it is logical to expect that combinations of these 2 classes of antineoplastic agents would prove more efficacious than either one alone. Yet 4 large randomized phase III trials of chemotherapy with or without an EGFR tyrosine kinase inhibitor in unselected patients with advanced-stage NSCLC, altogether totaling > 4000 patients, did not demonstrate improvement in clinical outcomes with the combination. Whether these negative results will be reproduced in ongoing combination studies of chemotherapy plus monoclonal antibodies directed against EGFR remain to be determined. Herein, we review recent preclinical and clinical data addressing this topic and explore the biologic rationale for developing new combination strategies based on patient selection by molecular and clinical factors, or by pharmacodynamic parameters.

KW - Antineoplastic agents

KW - Monoclonal antibodies

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=34147105416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147105416&partnerID=8YFLogxK

U2 - 10.3816/CLC.2007.s.003

DO - 10.3816/CLC.2007.s.003

M3 - Article

C2 - 17382026

AN - SCOPUS:34147105416

VL - 8

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - SUPPL. 2

ER -